BIPOLAR DISORDER · White paper
Bipolar Disorder Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About bipolar disorder — and why its trials are hard
Bipolar disorder is a chronic mood disorder marked by cycling episodes of mania or hypomania and depression, with an average onset around age 25 and a strong hereditary component. Management rests on mood stabilizers (lithium, divalproex), atypical antipsychotics, and the anticonvulsant lamotrigine, often used in combination and long term. Clinical trials are notoriously difficult: symptom heterogeneity across manic, depressive, and mixed states, high placebo response rates, comorbid conditions, and the need for extended follow-up to capture relapse all undermine signal detection. Standardized instruments anchor the endpoints used for approval, principally the Young Mania Rating Scale (YMRS) for mania, the MADRS and Hamilton Depression Rating Scale for depression, and time-to-relapse or time-to-recurrence for maintenance studies. Regulators increasingly value patient-reported outcomes and functional measures alongside symptom scores. Because chronic treatment carries metabolic, renal, dermatologic, and teratogenic risks, tolerability and adherence are integral efficacy considerations rather than afterthoughts in bipolar trial design.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Lithium (Eskalith/Lithobid) | 1970 | Acute mania and maintenance | Pediatric bipolar I RCT (ages 7-18) | YMRS change at 8 weeks | Lithium -12.9 vs placebo -7.3 (difference ~5.5); maintenance discontinuation HR 0.28 |
| Divalproex sodium (Depakote) | 1994 | Acute manic episodes of bipolar I | Placebo-controlled mania trials | Manic symptom reduction (MRS/YMRS) | Superior to placebo in acute mania (whitepaper cites 1996 label date) |
| Olanzapine (Zyprexa) | 2000 | Acute manic/mixed episodes; maintenance (bipolar indication) | 3-4 week placebo-controlled monotherapy trials | YMRS total score; time to relapse | Superior to placebo on YMRS; relapse 50% by day 59 (olanzapine) vs day 23 (placebo) |
| Quetiapine (Seroquel) | 2004 | Bipolar mania (2004) and bipolar depression (2006) | BOLDER-type 8-week depression trials; 3-week mania trials | MADRS (depression); YMRS (mania) | Depression: 300 mg MADRS -17.4 vs placebo -11.9; mania YMRS significant vs placebo |
| Lamotrigine (Lamictal) | 2003 | Maintenance treatment of bipolar I (delay of mood episodes) | Maintenance relapse-prevention RCTs | Time to intervention for a mood episode | Prolonged time to depressive episodes vs placebo; particularly effective against depression |
| Lurasidone (Latuda) | 2013 | Bipolar I depression, monotherapy and adjunct to lithium/valproate | PREVAIL monotherapy and adjunctive trials | MADRS change at 6 weeks | Statistically significant MADRS reduction vs placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in bipolar disorder development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Allopurinol — NCT00643123 | No greater reduction in manic symptoms than placebo | Purinergic/uric-acid hypothesis did not translate to clinical benefit as an adjunct |
| Galantamine hydrobromide — NCT00741598 | Safe and tolerated but ineffective for cognitive deficits in bipolar disorder | Cholinesterase-inhibitor mechanism effective in Alzheimer's did not extend to bipolar cognition |
| Sodium benzoate — GDCT0235621 | No evidence of efficacy as adjunctive treatment in early psychosis | NMDA-modulating (D-amino acid oxidase inhibition) approach failed to show benefit |
Choosing the right endpoint
Primary endpoints that matter in bipolar disorder trials
- YMRS (Young Mania Rating Scale) — Primary manic-symptom endpoint in acute mania trials
- MADRS / HDRS — Standard depression severity scales for bipolar depression efficacy
- Time to relapse/recurrence — Critical maintenance endpoint given high relapse risk; requires long follow-up
- Functional outcomes (GAF, Sheehan Disability Scale) — Quantify occupational, social, and cognitive impact beyond symptoms
- Tolerability (UKU, SAFTEE) — Adverse-event burden central to adherence in chronic therapy
How iNGENū runs bipolar disorder trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Bipolar Disorder clinical trials — FAQs
Why are placebo response rates a problem in bipolar trials?
What is the most common primary endpoint for acute mania?
Why is long-term follow-up essential in bipolar research?
Ready to discuss your bipolar disorder trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal